SK283679B6 - Deriváty sulfonylmočoviny - Google Patents

Deriváty sulfonylmočoviny Download PDF

Info

Publication number
SK283679B6
SK283679B6 SK982-99A SK98299A SK283679B6 SK 283679 B6 SK283679 B6 SK 283679B6 SK 98299 A SK98299 A SK 98299A SK 283679 B6 SK283679 B6 SK 283679B6
Authority
SK
Slovakia
Prior art keywords
urea
diisopropylphenyl
chloro
sulfonyl
hexahydro
Prior art date
Application number
SK982-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK98299A3 (en
Inventor
Mark Anthony Dombroski
James Frederick Eggler
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK98299A3 publication Critical patent/SK98299A3/sk
Publication of SK283679B6 publication Critical patent/SK283679B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK982-99A 1997-01-29 1997-12-29 Deriváty sulfonylmočoviny SK283679B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29
PCT/IB1997/001603 WO1998032733A1 (en) 1997-01-29 1997-12-29 Sulfonyl urea derivatives and their use in the control of interleukin-1 activity

Publications (2)

Publication Number Publication Date
SK98299A3 SK98299A3 (en) 2001-10-08
SK283679B6 true SK283679B6 (sk) 2003-11-04

Family

ID=21891776

Family Applications (1)

Application Number Title Priority Date Filing Date
SK982-99A SK283679B6 (sk) 1997-01-29 1997-12-29 Deriváty sulfonylmočoviny

Country Status (40)

Country Link
US (2) US6166064A (zh)
EP (1) EP0964849B1 (zh)
JP (1) JP3573757B2 (zh)
KR (1) KR100324058B1 (zh)
CN (1) CN1127479C (zh)
AP (1) AP929A (zh)
AR (1) AR011093A1 (zh)
AT (2) ATE242208T1 (zh)
AU (1) AU723895B2 (zh)
BG (1) BG103597A (zh)
BR (1) BR9714328A (zh)
CA (1) CA2279186C (zh)
CO (1) CO4920230A1 (zh)
CZ (1) CZ293173B6 (zh)
DE (2) DE69729762T2 (zh)
DK (2) DK0964849T3 (zh)
DZ (1) DZ2407A1 (zh)
EA (1) EA001803B1 (zh)
ES (2) ES2198598T3 (zh)
HR (1) HRP980045B1 (zh)
HU (1) HUP0000567A3 (zh)
ID (1) ID22223A (zh)
IL (1) IL130855A0 (zh)
IS (1) IS5099A (zh)
MA (1) MA26468A1 (zh)
NO (1) NO313279B1 (zh)
NZ (1) NZ336248A (zh)
OA (1) OA11079A (zh)
PA (1) PA8444701A1 (zh)
PE (1) PE57898A1 (zh)
PL (1) PL335052A1 (zh)
PT (2) PT1270565E (zh)
SK (1) SK283679B6 (zh)
TN (1) TNSN98017A1 (zh)
TR (1) TR199901816T2 (zh)
TW (1) TW515788B (zh)
UY (1) UY24861A1 (zh)
WO (1) WO1998032733A1 (zh)
YU (1) YU33799A (zh)
ZA (1) ZA98685B (zh)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (en) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulfonylurea binding proteins
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
EP1214087A1 (en) * 1999-09-14 2002-06-19 Pfizer Products Inc. Combination treatment with il-1ra and compounds that inhibit il-1 processing and release
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
WO2003024948A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
DK1572946T3 (da) 2002-09-06 2012-07-02 Amgen Inc Terapeutisk humant monoklonalt anti-IL-1R1-antistof
WO2004031777A1 (en) * 2002-10-03 2004-04-15 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
RU2006106920A (ru) 2003-08-06 2007-09-20 Синомикс Инк. (Us) Гетеро-олигомерные вкусовые рецепторы t1r, клеточные линии, которые экспрессируют указанные рецепторы и вкусовые соединения
EP1776336B1 (en) * 2004-03-23 2009-09-30 DOMPE' pha.r.ma s.p.a. 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10385040B2 (en) 2014-08-12 2019-08-20 Loyola University Of Chicago Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
MD3259253T2 (ro) * 2015-02-16 2020-06-30 Univ Queensland Sulfoniluree și compuși înrudiți și utilizări ale acestora
US10688077B2 (en) * 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
WO2017184604A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3272739A1 (en) * 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
JP2020502064A (ja) * 2016-11-29 2020-01-23 エピザイム，インコーポレイティド スルホン酸基を含むｋａｔ阻害剤としての化合物
TW201837021A (zh) 2017-01-23 2018-10-16 美商傑庫爾醫療股份有限公司 作為介白素-1活性抑制劑之化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
ES2906280T3 (es) 2017-07-07 2022-04-18 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
AU2018307743C1 (en) 2017-07-24 2021-09-09 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
KR20200041337A (ko) 2017-08-15 2020-04-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
AU2018317798A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
ES2927851T3 (es) * 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
EP3707134A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3817817A1 (en) * 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
CA3104199A1 (en) * 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
US12084416B2 (en) 2019-01-14 2024-09-10 Zydus Lifesciences Limited Substituted sulfonylurea derivatives
WO2020249667A1 (en) 2019-06-12 2020-12-17 NodThera Limited Sulfonylurea derivatives and uses thereof
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
JP2022548869A (ja) * 2019-09-12 2022-11-22 カディラ・ヘルスケア・リミテッド 新規な置換スルホキシミン誘導体
US20230219920A1 (en) * 2020-06-11 2023-07-13 Medshine Discovery Inc. Dimethylsulfoximine derivative
IL299084A (en) 2020-06-19 2023-02-01 Ac Immune Sa History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
IL301055A (en) 2020-09-04 2023-05-01 Nodthera Ltd Sulfamoylurea derivatives including an alkyl-oxycycloalkyl unit and their uses
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
CN118541366A (zh) 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
KR20240148839A (ko) * 2022-02-15 2024-10-11 에프. 호프만-라 로슈 아게 1,2,3,5,6,7-헥사히드로-s-인다센 유도체 제조를 위한 공정
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) * 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
CZ257599A3 (cs) 2000-09-13
AU5234098A (en) 1998-08-18
IS5099A (is) 1999-06-29
CN1245490A (zh) 2000-02-23
AU723895B2 (en) 2000-09-07
PT1270565E (pt) 2004-09-30
CN1127479C (zh) 2003-11-12
ATE242208T1 (de) 2003-06-15
NO993658L (no) 1999-09-28
AP9801190A0 (en) 1998-03-31
ES2222426T3 (es) 2005-02-01
AP929A (en) 2001-01-18
DE69729762T2 (de) 2005-07-14
PE57898A1 (es) 1999-06-11
UY24861A1 (es) 2000-09-29
ZA98685B (en) 1999-07-29
EP0964849A1 (en) 1999-12-22
US6433009B1 (en) 2002-08-13
IL130855A0 (en) 2001-01-28
PA8444701A1 (es) 2000-05-24
ID22223A (id) 1999-09-16
BG103597A (bg) 2000-02-29
CO4920230A1 (es) 2000-05-29
KR100324058B1 (ko) 2002-02-16
YU33799A (sh) 2002-03-18
TW515788B (en) 2003-01-01
PT964849E (pt) 2003-08-29
CA2279186C (en) 2004-02-24
ATE270285T1 (de) 2004-07-15
DE69722663T2 (de) 2004-04-29
DE69729762D1 (de) 2004-08-05
BR9714328A (pt) 2000-03-21
HRP980045A2 (en) 1999-06-30
SK98299A3 (en) 2001-10-08
DK0964849T3 (da) 2003-08-25
CZ293173B6 (cs) 2004-02-18
HRP980045B1 (en) 2002-10-31
JP2000511200A (ja) 2000-08-29
DZ2407A1 (fr) 2003-01-04
EP0964849B1 (en) 2003-06-04
DK1270565T3 (da) 2004-10-04
KR20000070541A (ko) 2000-11-25
HUP0000567A2 (hu) 2000-10-28
NO313279B1 (no) 2002-09-09
NO993658D0 (no) 1999-07-28
NZ336248A (en) 2000-10-27
HUP0000567A3 (en) 2002-10-28
EA001803B1 (ru) 2001-08-27
EA199900603A1 (ru) 2000-02-28
TNSN98017A1 (fr) 2005-03-15
TR199901816T2 (xx) 1999-11-22
PL335052A1 (en) 2000-03-27
US6166064A (en) 2000-12-26
AR011093A1 (es) 2000-08-02
CA2279186A1 (en) 1998-07-30
MA26468A1 (fr) 2004-12-20
WO1998032733A1 (en) 1998-07-30
OA11079A (en) 2002-03-14
JP3573757B2 (ja) 2004-10-06
ES2198598T3 (es) 2004-02-01
DE69722663D1 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
SK283679B6 (sk) Deriváty sulfonylmočoviny
US7700586B2 (en) Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
JP2003509378A (ja) ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法
EP1054667B1 (en) Bicyclic pyrrole compounds, pharmaceutical compositions containing them and their use as antiinflammatory and immunomodulating agents
US20090286771A1 (en) 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders
EA005210B1 (ru) Сульфонамиды гидроксидифенилмочевины в качестве антагонистов рецептора ил-8
JP2003510319A (ja) 医薬として活性なスルホンアミド誘導体
JPH10500997A (ja) アリール−及びヘテロアリール−スルホンアミド誘導体、その製造法及びエンドセリンアンタゴニストとしてのその用途
HU210057B (en) Process for the preparation of acetamide derivatives and pharmaceutical compositions containing the same
SK132498A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
WO1998044799A1 (en) Diarylsulfonylureas for use in treating secretory diarrhea
HU201004B (en) Process for producing nitromethane derivatives as well as pharmaceutical compositions containing them as active agent
EP1270565A1 (en) 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives
US4914101A (en) 3,4-Dihydro-2-alkyl-3-oxo-n-aryl-2H-(1)benzo-thieno(3,2-e)-1,2-thiazine-4-carboxamide-1,1-dioxides
MXPA99007030A (en) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6362205B2 (en) Substituted 3,3-diamino-2-propenenitriles, their preparation and use
SK284325B6 (sk) Substituované tiofénsulfonylmočoviny a - tiomočoviny, spôsob ich výroby, ich použitie a liečivo, ktoré ich obsahuje